Glenmark Pharmaceuticals Inc. received regulatory clearance on July 9, 2026, for the approved ANDA212555, positioning the company to enter the market for the oral nintedanib esylate generic. This approval is expected to intensify price competition within the late-stage fibrotic and oncology drug sectors, posing challenges to established branded offerings and driving significant down-sides for current market entrants.